Huge acquisition scores Novo Nordisk an FDA-ready treatment
Through acquiring Dicerna, Novo Nordisk is getting its hands on a drug candidate that is expected to be submitted for FDA approval during first quarter of 2022.
by mikkel aabenhus hemmingsen and ulrich quistgaard, translated by catherine brett
In around a year's time, Novo Nordisk may be able to enter a new market with an approved treatment under its belt, after its USD 3.3bn acquisition of Dicerna.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
.jpg)
.jpg&w=384&q=75)
